ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company in China, announced today

First Page		Document Content
Date: 2015-07-30 04:30:57 Chronic lower respiratory diseases Respiratory therapy Respiratory diseases Asthma Chronic obstructive pulmonary disease Chronic condition Sanofi Bronchial hyperresponsiveness Obstructive lung disease Firestone Institute for Respiratory Health		ZAI Lab announces a global licensing agreement with Sanofi for two novel compounds in chronic respiratory diseases ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company in China, announced today Add to Reading List Source URL: www.zailaboratory.com Download Document from Source Website File Size: 359,53 KB Share Document on Facebook

	Chronic Obstructive Pulmonary Disease: Open Access DocID: 1rMT2 - View Document
	DOC Document DocID: 1rs8N - View Document
	The Dangers to Health from Health Effects of Wood Smoke Exposures W DocID: 1rkGG - View Document
	Statement of Israel Rappaport Before the House Committee on Interstate and Foreign Commerce on Bills Relating to Cigarette Labeling and Advertising DocID: 1rc0I - View Document
	LIES, DAMNED LIES, & 400,000 SMOKING-RELATED DEATHS by Robert A. Levy and Rosalind B. Marimont T RUTH WAS AN EARLY VICTIM in the battle against tobacco. The big lie, repeated ad nauseam in anti-tobacco circles, is that s DocID: 1rbkp - View Document